Islamabad, May 13th, 2020, (Press Release): Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of Remdesivir.
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of Remdesivir. The agreements allow the companies – Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan – to manufacture Remdesivir for distribution in 127 countries. The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access.
Bilawal Bhutto expresses grief at the passing of senior PPP activist
More than 2,000 new cases of corona in Pakistan in 24 hours
Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for Remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than Remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier.
Pakistani actress’ prayers have been answered
67% Population Lost Jobs During Lockdown, 74% Now Eating Lesser
- The agreements permit distribution in the following countries:
- Afghanistan
- Algeria
- Angola
- Anguilla
- Antigua & Barbuda
- Armenia
- Aruba
- Azerbaijan
- Bahamas, The
- Bangladesh
- Barbados
- Belarus
- Belize
- Benin
- Bermuda
- Bhutan
- Botswana
- British Virgin Islands
- Burkina Faso
- Burundi
- Cambodia
- Cameroon
- Cape Verde
- Cayman Island
- Central Af R.
- Chad
- Comoros
- Congo Rep.
- Cook Islands
- Costa Rica
- Cote d’Ivoire
- Cuba
- Curacao
- Djibouti
- Dominica
- Dominican Republic
- Egypt
- El Salvador
- Equatorial Guinea
- Eritrea
- Eswatini (Swaziland)
- Ethiopia
- Fiji
- Gabon
- Gambia, The
- Georgia
- Ghana
- Grenada
- Guatemala
- Guinea
- Guinea Bis
- Guyana
- Haiti
- Honduras
- India
- Indonesia
- Jamaica
- Kazakhstan
- Kenya
- Kiribati
- Korea, Dem. People’s Rep. (North Korea)
- Kyrgyzstan
- Lao DR (Laos)
- Lesotho
- Liberia
- Libya
- Madagascar
- Malawi
- Maldives
- Mali
- Marshall Islands
- Mauritania
- Mauritius
- Micronesia, Fed. Sts.
- Moldova
- Mongolia
- Montserrat
- Morocco
- Mozambique
- Myanmar
- Namibia
- Nauru
- Nepal
- Nicaragua
- Niger
- Nigeria
- Pakistan
- Palau
- Panama
- Papua New Guinea
- Philippines
- Rwanda
- Samoa
- Sao Tome and Principe
- Senegal
- Seychelles
- Sierra Leone
- Sint Maarten (Dutch part)
- Solomon Islands
- Somalia
- South Africa
- South Sudan
- Sri Lanka
- St. Kitts and Nevis
- St. Lucia
- St. Vincent and the Grenadines
- Sudan
- Suriname
- Tajikistan
- Tanzania
- Thailand
- Timor-Leste
- Togo
- Tonga
- Trinidad & Tobago
- Tunisia
- Turkmenistan
- Turks & Caicos
- Tuvalu
- Uganda
- Ukraine
- Uzbekistan
- Vanuatu
- Vietnam
- Zambia
- Zimbabwe
3,525 new cases of coronavirus infection and 122 deaths
Aamir Khan’s longtime assistant Amos passed away
About Remdesivir:
Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials, and the safety and efficacy of Remdesivir for the treatment of COVID-19 are not yet established. Remdesivir has not been approved by the U.S. FDA for any use.
For information about the authorized use of Remdesivir and mandatory requirements of the Emergency Use Authorization in the U.S., please review the Fact Sheet for Healthcare Providers and FDA Letter of Authorization available at www.gilead.com/remdesivir.
Khalil ur Rehman to write something similar to Diriliş: Ertuğrul
Forward Looking Statement:
This statement includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. Remdesivir is an investigational drug that has not been approved by the FDA for any use, and it is not yet known if remdesivir is safe or effective for the treatment of COVID-19. There is the possibility of unfavorable results from ongoing and additional clinical trials involving remdesivir and the possibility that Gilead and other parties may be unable to complete one or more of such trials in the currently anticipated timelines or at all.
Further, it is possible that Gilead may make a strategic decision to discontinue development of remdesivir or that FDA and other regulatory agencies may not approve remdesivir, and any marketing approvals, if granted, may have significant limitations on its use. As a result, remdesivir may never be successfully commercialized. In addition, Gilead may face challenges related to the allocation and geographical distribution of existing and future supply of remdesivir.
COVID-19: Qatari government gives big shock to Modi government
If Gilead and its manufacturing partners are unable to sufficiently scale up the production of remdesivir in the currently anticipated timelines, Gilead may be unable to meet global supply needs. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Stay tuned to Baaghi TV for the latest news and updates.
